On Friday, Extreme Networks, Inc (NASDAQ:EXTR)’s shares declined -22.84% to $2.50, hitting its lowest level, as Extreme Networks, declared preliminary unaudited results for the quarter ended March 31, 2015. The estimates for non-GAAP proceed for the quarter ended March 31, 2015 comprise purchase accounting adjustments for deferred proceed of about $0.8 million related to our attainment of Enterasys Networks. The estimates for non-GAAP gross margin comprise adjustments of about $4.3 million for amortization of intangibles, about $0.8 million for purchase accounting adjustments and about $0.5 million stock based compensation expense.
Extreme will release and talk about its final results for the third quarter ending March 31, 2015 and guidance for the fourth quarter, on Wednesday May 6, 2015, in a press release followed by conference call at 5:00 p.m. ET.
Extreme Networks, Inc., together with its auxiliaries, provides wired and wireless network infrastructure equipment, software, and services for enterprises, data centers, and service providers.
WPCS International Incorporated (NASDAQ:WPCS)’s shares dropped -13.21% to $0.230, during the last trading session on Friday, as WPCS International Incorporated, declared that its domestic operation was awarded $14.4 million in new contracts during the month of March 2015.
Sebastian Giordano, Interim CEO of WPCS, commented, “While we continue our corporate restructuring efforts, we are extremely happy to see our core Suisun City business continue to capitalize upon its stellar reputation as a leading provider of low voltage and structured building communications cabling.
WPCS International Incorporated provides low voltage communication infrastructure services in the public services, healthcare, energy, and corporate enterprise markets worldwide.
At the end of Friday’s trade, AngioDynamics, Inc. (NASDAQ:ANGO)‘s shares dipped -9.42% to $16.53, as AngioDynamics, declared a worldwide licensing contract with privately-held EmboMedics Inc., of Minneapolis, Minn., which develops injectable and resorbable microspheres. Embolization is the fastest growing segment in Interventional Radiology, and this newly formed planned relationship will allow AngioDynamics to leverage the talent and knowledge of its sales team to re-enter the about $150 million addressable global embolic market.
AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The corporation offers manifolds, contrast administration systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that assist clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, counting laser system products used in endovascular laser procedures to treat superficial venous diseases, in addition to sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities.
Uniqure NV (NASDAQ:QURE), ended its Friday’s trading session with -7.63% loss, and closed at $28.44, as uniQure, disclosed the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are predictable to be about $82.4 million.
In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is predictable to close on or about April 15, 2015.
uniQure N.V., a biopharmaceutical corporation, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The corporation offers Glybera for the treatment of patients with lipoprotein lipase deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
